Hugh Davis

About Hugh Davis

Dr. Davis has over 35 years of scientific leadership and business experience in discovery research, early development, business development, strategic alliance, company operations and executive management in large pharma as the VP and Head of Biologics Clinical Pharmacology at Johnson & Johnson, in private biotech as the Chief Business and Development Officer at Biosion, Inc, in a CRO as Chief Business Officer at Frontage Laboratories (HKEX: 1521) and in a public US company as President and COO at Aclaris Therapeutics, Inc.(Nasdaq: ACRS). He is an established expert in the discovery and development of innovative biologics, from target ID/validation through creation of IND/CTA packages and execution of clinical programs across numerous therapeutic areas, especially oncology, immuno-oncology, immunology and cardiovascular medicine. Dr. Davis earned his Ph.D. and M.S. degrees in Biochemistry from Villanova University and a B.S. degree in Chemistry from Gannon University. He has published extensively, including authorship of over 75 scientific research articles and book chapters. Dr. Davis is currently serving on the Board of Directors of Aclaris Therapeutics, Inc. and Biosion, Inc. and on the Board of Directors and Scientific Advisory Board of Anewcro, LLC.

Experience

1. President, Chief Operating Officer and Member of the Board of Directors

   Aclaris Therapeutics, Inc

   Nov 2024 — Present

Education

• Villanova University

  Master of Science (M.S.), Biochemistry

  1980 — 1983

• Villanova University

  Ph.D., Biochemistry

  1980 — 1985

Skills

• Pharmaceutical Industry
• Life Sciences
• Drug Discovery
• Biologics
• Clinical Research
• Clinical Pharmacology
• Clinical Trials
• Oncology
• Drug Development
• Gcp
• Biopharmaceuticals
• Validation
• Translational Medicine
• Infectious Diseases
• Clinical Development
• Medical Affairs
• Regulatory Submissions
• CRO
• Biotechnology
• Immunology